Protocol summary
-
Study aim
-
The aim of this study is to determine the effects of omega-3 fatty acid supplementation on metabolic profiles, inflammatory factor and biomarkers of oxidative stress in diabetic nephropathy patients.
-
Design
-
Randomized, double-blind, placebo-controlled clinical trial, phase 2, 60 patients
-
Settings and conduct
-
60 patients with diabetic nephropathy of eligible and referred to Akhavan Clinic, Kashan, Iran in the study will be selected.
-
Participants/Inclusion and exclusion criteria
-
Patients with diabetic nephropathy with a proteinuria level>0.3 g/24 h, with or without elevation of serum creatinine levels and aged 45 to 85 years will be included in this study. Exclusion criteria:
the intake of omega-3 fatty acid supplements within 3 months,
patients with uncontrolled diabetes, the current use of warfarin,
malignancy and/or liver cirrhosis.
-
Intervention groups
-
Patients will be assigned to receive either omega-3 fatty acid (intervention group: n=30) or placebo (control group: n=30).
-
Main outcome variables
-
Metabolic profiles, inflammatory factor and biomarkers of oxidative stress
General information
-
Reason for update
-
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT201502255623N36
Registration date:
2015-03-10, 1393/12/19
Registration timing:
prospective
Last update:
2019-09-16, 1398/06/25
Update count:
1
-
Registration date
-
2015-03-10, 1393/12/19
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
Kashan University of Medical Sciences
-
Expected recruitment start date
-
2015-03-11, 1393/12/20
-
Expected recruitment end date
-
2015-03-15, 1393/12/24
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Effects of omega-3 fatty acid supplementation on metabolic profiles, hs-CRP and biomarkers of oxidative stress in diabetic nephropaty patients
-
Public title
-
Effects omega-3 fatty acid supplementation in the treatment of diabetes
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Patients with diabetic nephropathy aged 45 to 85 years.
Proteinuria level>0.3 g/24 h, with or without elevation of serum creatinine levels
Exclusion criteria:
The intake of omega-3 fatty acid supplements within 3 months
Patients with uncontrolled diabetes
The current use of warfarin
Malignancy and/or liver cirrhosis.
-
Age
-
From 45 years old to 85 years old
-
Gender
-
Both
-
Phase
-
2
-
Groups that have been masked
-
- Participant
- Investigator
- Outcome assessor
-
Sample size
-
Target sample size:
60
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
To decrease potential confounding effects, all participants will have stratified randomization according to BMI and age. Then, participants in each block will be randomly allocated into two treatment groups to take either omega-3 fatty acid supplement or placebo. Randomization will be done by the use of Stat Trek software. https://stattrek.com/statistics/random-number-generator.aspx
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Randomization and allocation will be concealed from the researchers and participants until the final analyses are completed. Another person at the Akhavan Clinic in Kashan who is not involved in the trial and not aware of random sequences, will be assigned the participants to the numbered bottles of capsules.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2015-02-28, 1393/12/09
-
Ethics committee reference number
-
93211
Health conditions studied
1
-
Description of health condition studied
-
Diabetic nephropathy
-
ICD-10 code
-
E10
-
ICD-10 code description
-
Insulin-dependent diabetes mellitus
Primary outcomes
1
-
Description
-
Insulin resistance
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Calculation using HOMA formula
2
-
Description
-
Insulin
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
ELISA kit
Secondary outcomes
1
-
Description
-
High-sensitivity C-reactive protein
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
ELISA test
2
-
Description
-
Malondialdehyde
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Spectrophotometry
3
-
Description
-
Glutathione
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Spectrophotometry
4
-
Description
-
Total antioxidant capacity
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Spectrophotometry
5
-
Description
-
Nitric oxide
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Spectrophotometry
6
-
Description
-
Triglycerides
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Enzymatic kit
7
-
Description
-
Total cholesterol
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Enzymatic kit
8
-
Description
-
HDL
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Enzymatic kit
9
-
Description
-
Fasting blood sugar
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Enzymatic kit
10
-
Description
-
LDL
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Enzymatic kit
11
-
Description
-
Blood Urea Nitrogen
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Spectrophotometry
12
-
Description
-
Serum Creatinine
-
Timepoint
-
Baseline and End-of-trial
-
Method of measurement
-
Spectrophotometry
Intervention groups
1
-
Description
-
Intervention group: Omega-3 fatty acid pearl, 1000 mg, daily, for 12 weeks orally.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Placebo pearl, daily, for 12 weeks orally.
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Kashan University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available